Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1996-06-25
1998-07-07
Bond, Robert T.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
540518, A61K 3155, C07D24312
Patent
active
057769290
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention relates to novel benzodiazepine derivatives capable of competing with gastrin and/or CCK-B and binding to their receptors, and pharmaceutical compositions which contain the same and are useful in the treatment of various diseases associated with gastrin and/or CCK-B receptors.
BACKGROUND OF THE INVENTION
Gastrin and cholecystokinin (CCK) are physiologically active substances belonging to what is called a gastrin sub-family of the gastrointestinal peptide hormone family. Although gastrin receptors are commonly found in various tissues including the whole superior digestive tract, pancreas, liver, biliary duct and the like, they mainly exist on parietal cells of fundic glands and participate in the mediation of gastric acid secretion. As for CCK receptors, it is known that there are two types of receptors, i.e., CCK-A receptor found in peripheral tissues such as digestive gut and CCK-B receptor found in brain. The former participates in the control of gut motility and pancreas secretion whereas the latter in the control of central nervous action, appestat and the like. Accordingly, it has been expected that compounds capable of competing with gastrin and/or CCK-B and binding to their receptors are useful in the treatment of animals including human suffering from gastrointestinal and central nervous diseases associated with receptors for these peptide hormones. For example, such compounds are thought to be useful as an anti-tumor agent; a drug for treating pancreatitis, gallbladder disorder or irritable bowel syndrome, for relieving biliary colic, and for improving appetite. Further, investigations into receptors in both gastrointestinal and central nervous system revealed that these gastrointestinal peptide Peptides" Taisha, vol. 18, No. 10, 33-44 (1981); J. Hughus, C. Woodruff, D. Horwell, A. McKnight & D. Hill, "Gastrin", J. H. Walsh ed., Rovan Press, Ltd., New York, 1993, p. 169-186; F. Makovec, Drugs of the Future, 18, 919 (1993); Japanese Patent Publication (KOKAI) 63-238069, EP 167,919; U.S. Pat. No. 4,820,834; EP 284,256; U.S. Pat. No. 5,004,741!.
For instance, gastrin antagonists specific to gastrin receptors are thought to be effective on gastrin-associated disorders such as peptic ulcers in gaster and duodenum, Zollinger-Ellison syndrome, hyperplasia of sinus C cells, and decrease in gastrin activity. The usefulness of antagonists specific to gastrin-receptor in the treatment of gastric and duodenal ulcers has been reported (Taisha, 29/7, 1992, R. Eissele, H. Patberg, H. Koop, W.
Krack, W. Lorenz, A. T. McKnight & R. Arnold, Gastroenterology, 103, 1596 (1992), etc.)
There have been reported that antagonists against CCK-B receptor are useful in the reinforcement and elongation of the analgetic effect of opioid-type compounds (e.g., morphine derivatives such as morphine sulfate or the future 18, 919 (1993); Proc. Natl. Acad. Sci. USA, Vol. 87, p. 71, 05 September 1990, Neurobiology!.
It is necessary to use a compound capable of binding to an intended peptide hormone receptor in preference discriminating it from that for peptide hormones of different sub-types in order to conduct treatment more efficiently.
A series of benzodiazepine derivatives which are antagonistic against gastrin or CCK-B receptor have been disclosed (WO 93/14074 and WO 93/14075). However, they failed to disclose any specific pharmacological data regarding antagonistic activity against gastrin receptors, or antagonists useful as a medicine. Further, all the compounds disclosed in these publications are racemates with an asymmetric carbon atom at the 3-position, which makes the preparation thereof difficult and requires optical resolution to obtain a single compound.
Accordingly, it has been strongly demanded to develop a compound which can bind to an intended receptor discriminating it from other peptide hormone receptor, and is useful as a drug and producible in ease.
DISCLOSURE OF THE INVENTION
In the situations above, the present inventors have studied intensively to develop c
Haga Nobuhiro
Hagishita Sanji
Ishihara Yasunobu
Kamata Susumu
Seno Kaoru
Bond Robert T.
Shionogi & Co. Ltd.
LandOfFree
Benzodiazepine derivative does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzodiazepine derivative, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzodiazepine derivative will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1206105